UA122152U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis includes clinical examination, examination of low and high density lipoprotein cholesterol levels, arteriography. Determine the serum polymorphism of MTHFR C677T, eNOS T786C genes, thrombomodulin content, folic acid, homocysteine, PSA, TGF- (1. In homozygous carrier 677-TT, 786-CC, thrombomodol levels 6 <6 ng / ml, homocysteine> 20 μmol / l, PSA> 6 mg / l, TGF- (1 <14 ng / ml diagnose the development of atherosclerosis.

Description

A useful model belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of cholesterol levels of low and high density lipoproteins, arteriography (Okorokov A.N. Diagnostics of diseases of internal organs. - Vol. 6. - M.: Med. Lit., 2003. - P. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that the method of diagnosing the development of atherosclerosis, which includes a clinical examination, research on the levels of cholesterol of low and high density lipoproteins, arteriography, according to a useful model, determines in the blood serum the polymorphism of the genes of methylenetetrahydrofolate reductase (MITNEK C677T), nitric oxide synthase (emoz T786С ), the content of thrombomodulin, folic acid, homocysteine, C-reactive protein (CRP), transforming growth factor beta 1 (TGF-DI1), with homozygous carrier 677-177, 786-SS, levels of thrombomodulin 25 ng/ml, folic acid " 6 ng/ml, homocysteine 220 μmol/l,

SRP "6 mg/l, TFR-R1 "14 ng/ml diagnose the development of atherosclerosis.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. Polymorphism of MTNEV C677y, emMmo5 T786C genes, thrombomodulin, folic acid, homocysteine, SRP, TFR-B1 content are determined in serum. At homozygous carriers of 677-TT, 786-SS, levels of thrombomodulin 25 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, SRP 26 mg/l, TFR-DV1 "14 ng/ml diagnose the development of atherosclerosis.

An example of using the method

Patient V., 56 years old, was hospitalized with a diagnosis of rheumatoid arthritis. Inspected.

Low and high density lipoprotein cholesterol levels were studied. An arteriography of vessels was performed. There are no signs of atherosclerosis. Polymorphism of MTNEV genes was determined in blood serum

C677T and emMmo5 T7860. The content of thrombomodulin, folic acid, homocysteine, SRP, TGF-D1 was determined by immunoenzymatic method. Homozygous carriers of 677-TT and 786-C0 were established.

Levels of thrombomodulin - 10.9 ng/ml, folic acid - 3.5 ng/ml, homocysteine - 30 μmol/l, SRP - 19 mg/l, TFR-D1 - 6.8 ng/ml. The development of atherosclerosis was diagnosed. Arteriographic signs of the latter were detected only after 13 months.

Thus, the proposed method allows diagnosing atherosclerosis in the early stages.

Claims (1)

USEFUL MODEL FORMULA The method of diagnosing the development of atherosclerosis, which includes a clinical examination, level research 40 low- and high-density lipoprotein cholesterol, arteriography, which is distinguished by the fact that the polymorphism of MTNEV C677T, eMO5 1786C genes, the content of thrombomodulin, folic acid, homocysteine, SRP, TFR-DI, in homozygous carriers of 677-TT, 786- SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, SRP 26 mg/l, TFR-DR1 "14 ng/ml diagnose the development of atherosclerosis.